新辅助化疗对进展期胃癌患者的近期疗效及不良反应的影响

The Effect of Neoadjuvant Chemotherapy on Short-term Efficacy and Toxicity of Patients with Advanced Gastric Cancer

目的探讨新辅助化疗对进展期胃癌患者近期疗效及不良反应的影响。方法 80例进展期胃癌患者被随机分为对照组(ECF化疗)和观察组(新辅助化疗),每组各40例,比较两组治疗的近期疗效、不良反应以及治疗前后生活质量。结果与对照组相比,观察组总有效率明显升高,差异有统计学意义(P<0.05);与对照组相比,观察组毒副作用发生率显著降低,差异有统计学意义(P<0.05);与对照组相比,观察组患者治疗后生活质量评分明显提高,差异有统计学意义(P<0.05)。结论新辅助化疗治疗进展期胃癌具有近期疗效显著、毒副作用少等特点,患者能较好地耐受化疗方案,值得临床推广。

Objective To study the effect of neoadjuvaut chemotherapy on short-term efficacy and toxicity of patients with advanced gastric cancer. Methods 80 patients with advanced gastric cancer were randomized into the control group （ ECF chemotherapy） and the observation group （neoadjuvant chemotherapy） according to the random number method,40 patients per group. The current clinical efficacy, toxicity, and the scores of life quality in the 2 groups were compared. Results Compared with the control group, the total effective rate was significantly increased in the observation group with statistical difference （P 〈 0. 05 ） ;compared with the control, group,the incidence of toxicity and side effects was obviously reduced in the observation group with statistical difference （ P 〈 0.05 ） ; compared with the control group, the score of quality of life after treatment was significantly increased in the observation group with statistical difference （ P 〈 0.05 ）. Conclusion The neoadjuvant chemotherapy in the treatment of advanced gastric cancer has the significant current efficacy, less toxicity and side effects with better patients＇ tolerance, and it is worthy of clinical promotion.